Answers are grounded in this paper and cite their sources.
BACKGROUND AND PURPOSE: (atsm) to inhibit ferroptosis. EXPERIMENTAL APPROACH: (atsm) was compared to the known antiferroptotic compound liproxstatin-1. KEY CONCLUSIONS AND IMPLICATIONS: (atsm) possesses favourable properties such as oral bioavailability and entry into the brain that make it an attractive investigational product for clinical trials of ferroptosis-related diseases.
No takes yet. Share an insight, caveat, or question.
Southon et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: